WuXi XDC Cayman Inc. (Stock code: 2268) has been successfully listed on the Main board of the HKEX on 17 Nov 2023, the maximum fund raising size is HK$3,675M.

WuXi XDC Cayman Inc. is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The Company conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The Company conducts its business in domestic and foreign markets.

CBI is honoured to be engaged in providing Due Diligence service with regards to this listing application.